36,271 Shares in Urogen Pharma $URGN Purchased by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. has acquired a new stake in Urogen Pharma, purchasing 36,271 shares valued at approximately $401,000, establishing ownership of 0.08% of the company.
• Despite a negative earnings report with a loss of ($1.05) per share, Urogen Pharma's stock has garnered several "buy" ratings from analysts, with an average target price of $31.43.
• Insider activity is notable as Mark Schoenberg sold 10,000 shares at an average price of $17.69, which reduced his ownership by 6.32%, and multiple insiders have sold 27,833 shares in the last 90 days.

Fox Run Management L.L.C. purchased a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 36,271 shares of the company's stock, valued at approximately $401,000. Fox Run Management L.L.C. owned about 0.08% of Urogen Pharma as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. CWM LLC grew its position in Urogen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Urogen Pharma in the 4th quarter valued at approximately $67,000. GAMMA Investing LLC grew its holdings in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Urogen Pharma in the 4th quarter worth about $101,000. Finally, ProShare Advisors LLC bought a new position in Urogen Pharma during the fourth quarter valued at approximately $137,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the sale, the insider owned 148,229 shares of the company's stock, valued at $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,833 shares of company stock worth $457,467 over the last 90 days. Corporate insiders own 4.70% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on URGN. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Piper Sandler began coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 target price for the company. HC Wainwright cut their target price on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, August 11th. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Tuesday, August 5th. Finally, Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $32.00.

Urogen Pharma Stock Down 1.7%

Urogen Pharma stock traded down $0.34 during midday trading on Friday, hitting $19.44. 1,039,838 shares of the stock were exchanged, compared to its average volume of 1,050,356. The company has a fifty day simple moving average of $16.50 and a two-hundred day simple moving average of $11.94. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.01. The stock has a market capitalization of $899.29 million, a PE ratio of -5.86 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, equities research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.